Cargando…

Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls

OBJECTIVE: To investigate changes in the cerebrospinal fluid (CSF) immunological profile after treatment switch from first-line injectables to rituximab in patients with relapsing-remitting MS (RRMS), and to compare the profile in MS patients with healthy controls (HC). METHOD: Cerebrospinal fluid f...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Flon, Pierre, Söderström, Lars, Laurell, Katarina, Dring, Ann, Sundström, Peter, Gunnarsson, Martin, Svenningsson, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805315/ https://www.ncbi.nlm.nih.gov/pubmed/29420590 http://dx.doi.org/10.1371/journal.pone.0192516

Ejemplares similares

Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis
por: Burman, Joachim, et al.
Publicado: (2023)

Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
por: Khademi, Mohsen, et al.
Publicado: (2013)

Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally
por: Svenningsson, Anders, et al.
Publicado: (2015)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing
por: Carlsson, Henrik, et al.
Publicado: (2021)

Inflammatory activity and vitamin D levels in an MS population treated with rituximab
por: Linden, Johan, et al.
Publicado: (2019)

Cerebrospinal fluid in multiple sclerosis
por: Rammohan, Kottil W.
Publicado: (2009)

The Cerebrospinal Fluid in Multiple Sclerosis
por: Deisenhammer, Florian, et al.
Publicado: (2019)

Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction
por: Vågberg, Mattias, et al.
Publicado: (2015)

Effect of resting pressure on the estimate of cerebrospinal fluid outflow conductance
por: Andersson, Kennet, et al.
Publicado: (2011)

Parkinsonian symptoms in normal pressure hydrocephalus: a population-based study
por: Molde, Karin, et al.
Publicado: (2017)

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid
por: Boman, Andrea, et al.
Publicado: (2016)

Metabolomics of Cerebrospinal Fluid in Multiple Sclerosis Compared With Healthy Controls: A Pilot Study
por: Židó, Michal, et al.
Publicado: (2022)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab
por: Holmøy, Trygve, et al.
Publicado: (2018)

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
por: Novakova, Lenka, et al.
Publicado: (2017)

Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis
por: Ehling, Rainer, et al.
Publicado: (2011)

Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis
por: CHEN, YAN, et al.
Publicado: (2016)

Cerebrospinal fluid GAP-43 in early multiple sclerosis
por: Rot, U, et al.
Publicado: (2018)

Cerebrospinal Fluid Analysis in Multiple Sclerosis Diagnosis: An Update
por: Lo Sasso, Bruna, et al.
Publicado: (2019)

The cerebrospinal fluid in multiple sclerosis: far beyond the bands
por: Domingues, Renan Barros, et al.
Publicado: (2017)

Cerebrospinal fluid cells immune landscape in multiple sclerosis
por: Li, Zijian, et al.
Publicado: (2021)

Cerebrospinal Fluid Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis
por: Costa, Júlia, et al.
Publicado: (2021)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Biomarkers in cerebrospinal fluid for amyotrophic lateral sclerosis phenotypes
por: Zhou, Jinxia, et al.
Publicado: (2023)

24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome
por: Björkhem, Ingemar, et al.
Publicado: (2018)

Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis
por: Guldbrandsen, Astrid, et al.
Publicado: (2020)

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
por: Al Nimer, Faiez, et al.
Publicado: (2016)

Cerebrospinal Fluid and Blood Biomarkers of Neuroaxonal Damage in Multiple Sclerosis
por: Dujmovic, Irena
Publicado: (2011)

Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis
por: Liu, Shilian, et al.
Publicado: (2009)

Oligoclonal Bands in Cerebrospinal Fluid of Black Patients with Multiple Sclerosis
por: da Gama, Paulo Diniz, et al.
Publicado: (2015)

The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis
por: Gray, Elizabeth, et al.
Publicado: (2015)

Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression
por: Albanese, Maria, et al.
Publicado: (2016)

Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis
por: Bernitsas, Evanthia, et al.
Publicado: (2017)

Serum and Cerebrospinal Fluid Cytokine Biomarkers for Diagnosis of Multiple Sclerosis
por: Martynova, Ekaterina, et al.
Publicado: (2020)

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
por: Ganapathy Subramanian, Ranjani, et al.
Publicado: (2021)

Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic
por: Wong, Jamie K, et al.
Publicado: (2023)

High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease
por: Degerman Gunnarsson, Malin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_br3nfh60s2togj4nf4q7o8r75c